Ultiva is a brand name of remifentanil, approved by the FDA in the following formulation(s):
ULTIVA (remifentanil hydrochloride - injectable; injection)
Manufacturer: MYLAN INSTITUTIONAL
Approval date: July 12, 1996
Strength(s): EQ 1MG BASE/VIAL, EQ 2MG BASE/VIAL, EQ 5MG BASE/VIAL [RLD]
Has a generic version of Ultiva been approved?
No. There is currently no therapeutically equivalent version of Ultiva available.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Ultiva. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: About generic drugs.
Related Patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
Stable formulations of remifentanil
Patent 5,866,591
Issued: February 2, 1999
Inventor(s): Gatlin; Larry Alan & Heiman; Shirley Ann & Lewis; Janet Sue
Assignee(s): Glaxo Wellcome Inc.
Stable formulations of 3-›4-methoxycarbonyl-4-›(1 -oxopropyl)phenylamino!-1-piperidine!propanoic acid, methyl ester, generally referred to as remifentanil, are disclosed. In particular, stabilized lyophilized solid composition are disclosed comprising certain acids, most preferably comprising glycine.Patent expiration dates:
- September 10, 2017✓
- March 10, 2018✓
- September 10, 2017
See also...
- Ultiva Consumer Information (Wolters Kluwer)
- Ultiva Consumer Information (Cerner Multum)
- Ultiva Advanced Consumer Information (Micromedex)
- Ultiva AHFS DI Monographs (ASHP)
- Remifentanil Consumer Information (Wolters Kluwer)
- Remifentanil Consumer Information (Cerner Multum)
- Remifentanil Intravenous Advanced Consumer Information (Micromedex)
- Remifentanil Hydrochloride AHFS DI Monographs (ASHP)
No comments:
Post a Comment